Evamont-L Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, designed to provide effective relief from allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a second-generation antihistamine, works by selectively blocking peripheral H1 receptors, thereby reducing symptoms like sneezing, runny nose, itching, and watery eyes without causing significant sedation. Montelukast, a leukotriene receptor antagonist, complements this action by inhibiting leukotrienes, which are inflammatory chemicals responsible for airway constriction, mucus production, and swelling in allergic reactions. Together, these components offer a comprehensive approach to managing allergy symptoms and improving respiratory function. Evamont-L is commonly prescribed for seasonal and perennial allergic rhinitis, asthma prophylaxis, and chronic idiopathic urticaria. It is generally well-tolerated, with minimal side effects such as headache, fatigue, or gastrointestinal discomfort. Patients should take Evamont-L as directed by a healthcare professional, usually once daily in the evening, to maximize its therapeutic benefits. Caution is advised in individuals with liver or kidney impairment, and it is important to inform the doctor about any other medications being taken to avoid potential interactions. This combination therapy enhances patient compliance by addressing multiple pathways of allergic inflammation in a single tablet.